Annual CFF
-$10.63 M
-$10.14 M-2074.23%
31 December 2023
Summary:
Exagen annual cash flow from financing activities is currently -$10.63 million, with the most recent change of -$10.14 million (-2074.23%) on 31 December 2023. During the last 3 years, it has fallen by -$10.54 million (-10860.82%). XGN annual CFF is now -115.47% below its all-time high of $68.73 million, reached on 31 December 2019.XGN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$121.00 K
+$105.00 K+46.46%
30 September 2024
Summary:
Exagen quarterly cash flow from financing activities is currently -$121.00 thousand, with the most recent change of +$105.00 thousand (+46.46%) on 30 September 2024. Over the past year, it has dropped by -$13.00 thousand (-12.04%). XGN quarterly CFF is now -100.19% below its all-time high of $65.08 million, reached on 31 March 2021.XGN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$667.00 K
-$13.00 K-1.99%
30 September 2024
Summary:
Exagen TTM cash flow from financing activities is currently -$667.00 thousand, with the most recent change of -$13.00 thousand (-1.99%) on 30 September 2024. Over the past year, it has increased by +$9.92 million (+93.70%). XGN TTM CFF is now -100.95% below its all-time high of $70.53 million, reached on 30 September 2019.XGN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XGN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2074.2% | -12.0% | +93.7% |
| 3 y3 years | -10000.0% | -196.8% | -101.0% |
| 5 y5 years | -193.1% | -100.2% | -101.0% |
XGN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -116.4% | at low | -196.8% | +98.8% | -101.0% | +93.8% |
| 5 y | 5 years | -115.5% | at low | -100.2% | +98.8% | -101.0% | +93.8% |
| alltime | all time | -115.5% | at low | -100.2% | +98.8% | -101.0% | +93.8% |
Exagen Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$121.00 K(-46.5%) | -$667.00 K(+2.0%) |
| June 2024 | - | -$226.00 K(+126.0%) | -$654.00 K(-93.9%) |
| Mar 2024 | - | -$100.00 K(-54.5%) | -$10.67 M(+0.4%) |
| Dec 2023 | -$10.63 M(+2074.2%) | -$220.00 K(+103.7%) | -$10.63 M(+0.4%) |
| Sept 2023 | - | -$108.00 K(-98.9%) | -$10.59 M(+0.8%) |
| June 2023 | - | -$10.24 M(>+9900.0%) | -$10.50 M(+1915.2%) |
| Mar 2023 | - | -$62.00 K(-64.2%) | -$521.00 K(+6.5%) |
| Dec 2022 | -$489.00 K(-100.8%) | -$173.00 K(+686.4%) | -$489.00 K(-7.6%) |
| Sept 2022 | - | -$22.00 K(-91.7%) | -$529.00 K(+38.5%) |
| June 2022 | - | -$264.00 K(+780.0%) | -$382.00 K(-10.7%) |
| Mar 2022 | - | -$30.00 K(-85.9%) | -$428.00 K(-100.7%) |
| Dec 2021 | $64.68 M(<-9900.0%) | -$213.00 K(-270.4%) | $64.68 M(-0.2%) |
| Sept 2021 | - | $125.00 K(-140.3%) | $64.81 M(+0.1%) |
| June 2021 | - | -$310.00 K(-100.5%) | $64.76 M(-0.4%) |
| Mar 2021 | - | $65.08 M(<-9900.0%) | $65.03 M(<-9900.0%) |
| Dec 2020 | -$97.00 K | -$82.00 K(-209.3%) | -$97.00 K(-94.6%) |
| Sept 2020 | - | $75.00 K(-292.3%) | -$1.81 M(-102.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | -$39.00 K(-23.5%) | $61.38 M(-5.9%) |
| Mar 2020 | - | -$51.00 K(-97.2%) | $65.21 M(-5.1%) |
| Dec 2019 | $68.73 M(+501.7%) | -$1.79 M(-102.8%) | $68.73 M(-2.5%) |
| Sept 2019 | - | $63.26 M(+1569.1%) | $70.53 M(+870.6%) |
| June 2019 | - | $3.79 M(+9.0%) | $7.27 M(+109.0%) |
| Mar 2019 | - | $3.48 M(+5.0%) | $3.48 M(-67.2%) |
| Dec 2018 | $11.42 M(-40.4%) | - | - |
| Dec 2017 | $19.16 M(+80.6%) | - | - |
| Dec 2015 | $10.61 M(+28.0%) | $3.31 M(+11.7%) | $10.61 M(+46.0%) |
| Sept 2015 | - | $2.96 M(+11.5%) | $7.26 M(-7.7%) |
| June 2015 | - | $2.66 M(+58.4%) | $7.87 M(+58.3%) |
| Mar 2015 | - | $1.68 M(-5340.6%) | $4.97 M(-39.9%) |
| Dec 2014 | $8.28 M(-26.8%) | -$32.00 K(-100.9%) | $8.28 M(-0.4%) |
| Sept 2014 | - | $3.57 M(-1576.0%) | $8.32 M(+75.3%) |
| June 2014 | - | -$242.00 K(-104.9%) | $4.74 M(-4.9%) |
| Mar 2014 | - | $4.99 M | $4.99 M |
| Dec 2013 | $11.31 M(+56.0%) | - | - |
| Dec 2012 | $7.25 M | - | - |
FAQ
- What is Exagen annual cash flow from financing activities?
- What is the all time high annual CFF for Exagen?
- What is Exagen annual CFF year-on-year change?
- What is Exagen quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Exagen?
- What is Exagen quarterly CFF year-on-year change?
- What is Exagen TTM cash flow from financing activities?
- What is the all time high TTM CFF for Exagen?
- What is Exagen TTM CFF year-on-year change?
What is Exagen annual cash flow from financing activities?
The current annual CFF of XGN is -$10.63 M
What is the all time high annual CFF for Exagen?
Exagen all-time high annual cash flow from financing activities is $68.73 M
What is Exagen annual CFF year-on-year change?
Over the past year, XGN annual cash flow from financing activities has changed by -$10.14 M (-2074.23%)
What is Exagen quarterly cash flow from financing activities?
The current quarterly CFF of XGN is -$121.00 K
What is the all time high quarterly CFF for Exagen?
Exagen all-time high quarterly cash flow from financing activities is $65.08 M
What is Exagen quarterly CFF year-on-year change?
Over the past year, XGN quarterly cash flow from financing activities has changed by -$13.00 K (-12.04%)
What is Exagen TTM cash flow from financing activities?
The current TTM CFF of XGN is -$667.00 K
What is the all time high TTM CFF for Exagen?
Exagen all-time high TTM cash flow from financing activities is $70.53 M
What is Exagen TTM CFF year-on-year change?
Over the past year, XGN TTM cash flow from financing activities has changed by +$9.92 M (+93.70%)